Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 19;10(8):2024.
doi: 10.3390/biomedicines10082024.

Tumor Temperature: Friend or Foe of Virus-Based Cancer Immunotherapy

Jason P Knapp  1 , Julia E Kakish  1 , Byram W Bridle  1   2 , David J Speicher  1   3   4
Affiliations
Review

Tumor Temperature: Friend or Foe of Virus-Based Cancer Immunotherapy

Jason P Knapp et al. Biomedicines. .

Abstract

The temperature of a solid tumor is often dissimilar to baseline body temperature and, compared to healthy tissues, may be elevated, reduced, or a mix of both. The temperature of a tumor is dependent on metabolic activity and vascularization and can change due to tumor progression, treatment, or cancer type. Despite the need to function optimally within temperature-variable tumors, oncolytic viruses (OVs) are primarily tested at 37 °C in vitro. Furthermore, animal species utilized to test oncolytic viruses, such as mice, dogs, cats, and non-human primates, poorly recapitulate the temperature profile of humans. In this review, we discuss the importance of temperature as a variable for OV immunotherapy of solid tumors. Accumulating evidence supports that the temperature sensitivity of OVs lies on a spectrum, with some OVs likely hindered but others enhanced by elevated temperatures. We suggest that in vitro temperature sensitivity screening be performed for all OVs destined for the clinic to identify potential hinderances or benefits with regard to elevated temperature. Furthermore, we provide recommendations for the clinical use of temperature and OVs.

Keywords: cancer; oncolytic virus; solid tumor; temperature.

PubMed Disclaimer

Conflict of interest statement

The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. B.W.B is the Chief Operating Officer of ImmunoCeutica Inc., a company dedicated to the research and development of immunoceuticals. ImmunoCeutica Inc. did not provide funding, nor did they influence this manuscript in any way. The research objectives of ImmunoCeutica Inc are independent of the subject matter of this manuscript. D.J.S. is the Director of Scientific Operations of Novometrix Research Inc., which specializes in integration of stakeholder networks and information synthesis; this mandate is unrelated to the content of this manuscript. Novometrix Research Inc. did not provide funding, nor did they influence this manuscript in any way. The other two authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1
The effects of oncolytic virus (OV) therapy and physiological changes on tumor temperature. OV therapy can increase tumor temperature by (A) causing fevers in recipients and (B) inducing antitumor immune responses, which increase inflammation and heat generation. OV therapy can also decrease tumor temperature by (C) destroying tumor vasculature and (D) causing direct oncolysis of tumor cells, which increases the number of necrotic regions. Physiological changes can also impact tumor temperature. Physiological changes such as (E) increased tumor vasculature and (F) increased metabolic activity of tumor cells can contribute to increases in tumor temperature. (G) Tumor cells have also been shown to overexpress procoagulants which can cause intravascular thrombosis, decreasing tumor temperature due to hypoxia, necrosis, and reduced metabolic activity of tumor cells.
See this image and copyright information in PMC

References

    1. Yahara T., Koga T., Yoshida S., Nakagawa S., Deguchi H., Shirouzo K. Relationship between Microvessel Density and Thermographic Hot Areas in Breast Cancer. Surg. Today. 2003;33:243–248. doi: 10.1007/s005950300055. - DOI - PubMed
    1. Owens A., Godbole M., Dabydeen D., Medeiros L., Phatak P., Kandlikar S. A comparative analysis of the tumor pathology and the metabolic heat generation of growing malignant tumors; Proceedings of the ASME 2020 18th International Conference on Nanochannels, Microchannels, and Minichannels collocated with the ASME 2020 Heat Transfer Summer Conference and the ASME 2020 Fluids Engineering Division Summer Meeting; Online. 13–15 July 2020; - DOI
    1. Sella T., Sklair-Levy M., Cohen M., Rozin M., Shapiro-Feinberg M., Allweis T.M., Libson E., Izhaky D. A Novel Functional Infrared Imaging System Coupled with Multiparametric Computerised Analysis for Risk Assessment of Breast Cancer. Eur. Radiol. 2013;23:1191–1198. doi: 10.1007/s00330-012-2724-7. - DOI - PubMed
    1. Arora N., Martins D., Ruggerio D., Tousimis E., Swistel A.J., Osborne M.P., Simmons R.M. Effectiveness of a Noninvasive Digital Infrared Thermal Imaging System in the Detection of Breast Cancer. Am. J. Surg. 2008;196:523–526. doi: 10.1016/j.amjsurg.2008.06.015. - DOI - PubMed
    1. Kateb B., Yamamoto V., Yu C., Grundfest W., Gruen J.P. Infrared Thermal Imaging: A Review of the Literature and Case Report. Neuroimage. 2009;47:T154–T162. doi: 10.1016/j.neuroimage.2009.03.043. - DOI - PubMed

LinkOut - more resources